The study is published in the Lancet (how ironic), and the conclusions (from the original study) state that 91-100% of participants (who received the vaccine) had high titers of antibodies for each strain of meningococcal B. By the way, the placebo group were in the 29-50% range for the placebo group.
Just in case you might wonder if there’s a placebo effect that causes an immune response to the bacteria, it’s probably not. There is usually a background seropositive individuals in a population, since individuals may be exposed to the bacteria on a usual basis. Even at 50%, the risk is so high that the vaccine (which is nearly 100% effective) is still necessary.
One more conclusion from the authors of the Lancet article:
No vaccine-related serious adverse events were reported and no significant safety signals were identified.
Just in case anyone was wondering.
Please comment below, positive or negative. Of course, if you find spelling errors, tell me! And share this article.
There are two ways you can help me out to keep this website awesome. First, you can make a monthly contribution through Patreon:Become a Patron!
Buy ANYTHING from Amazon.